Home > Healthcare > Medical Devices > Surgical Devices > heart lung machine market
Get a free sample of Heart-lung Machine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Heart-lung Machine Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Heart-Lung Machine Market size was valued at USD 343.2 million in 2022 and is projected to expand at over 4.3% CAGR from 2023 to 2032, owing to increasing prevalence of cardiovascular disorders, coupled with rising geriatric population base. Technological advancements pertaining to heart-lung machine and rising number of transplant surgeries is augmenting the product acceptance rate. Increasing awareness and initiatives to cater to appropriate diagnostic treatments and clinical benefits offered by heart-lung machines will propel the market growth.
Additionally, developing countries are emphasizing the expansion of healthcare infrastructure and an increase in the number of specialized cardiac centers, subsequently boosting the heart-lung machine market. Technological advancements, such as the development of miniaturized and portable systems, improved biocompatibility of components, and enhanced monitoring capabilities, will improve the efficiency of cardiac surgeries. Therefore, with the increasing healthcare expenditure, growing disposable income, aging population, and rising adoption of heart-lung machines.
Heart-lung machine, also known as a cardiopulmonary bypass (CPB) machine, is a medical device used for open-heart surgeries to temporarily take over the functions of the heart and lungs. The heart-lung machine performs the essential tasks of oxygenating the blood, removing carbon dioxide, and circulating the oxygenated blood back into the patient's body.
However, high cost of heart-lung machine can pose a significant challenge and impede the market demand. Heart-lung machines are highly sophisticated medical devices that require advanced technology and engineering. They incorporate intricate components, such as pumps, oxygenators, and monitoring systems, which contribute to their high production costs. The initial investment required to purchase heart-lung machine, especially those with advanced features and specifications, can result in financial challenges for healthcare facilities those with limited budgets. For instance, the cost of heart-lung machine can range between USD 10,000 to USD 50,000 and can vary according to the technology used in these machines
Additionally, these machines require regular maintenance, calibration, and replacement of components to ensure their proper functioning and safety. The cost of maintenance and servicing can add up over time, further increasing the overall cost of ownership. The heart-lung machine market growth can be hindered in developing economies having comparatively low-income levels attributed to the high costs of these machines. Thus, the high-end pricing associated with advanced heart-lung machines may drive down the acceptance rate of these devices.
North America market will reach around USD 141 million by 2032, attributable to the presence of key players in the region, an increasing prevalence of cardiovascular diseases, and rising awareness regarding the benefits of heart-lung machines.
The single roller pump held a dominant market share of around 60% in 2022, owing to several clinical benefits offered by single roller pump heart-lung machine such as propelling blood through the circuit, eliminating the need for complex mechanisms.
The market size of heart-lung machine was reached USD 343 million in 2022 and will reach over USD 520 million by 2032, due to increasing prevalence of cardiovascular disorders, coupled with rising number of transplant surgeries.
Braile Biomedica, Edwards Lifesciences Corp., ELITE LIFECARE, Eurosets Srl, Getinge AB, Heart Care India Co., Hemovent GmbH, Jarvik Heart Inc., Koninklijke Philips NV, LivaNova Plc, and Medtronic Plc.